← Back to Search

GBR 12909 for Cocaine Use Disorder

Phase 1
Waitlist Available
Led By Louis Cantilena, M.D.
Research Sponsored by National Institute on Drug Abuse (NIDA)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial will test if GBR 12909 can reduce the effects of cocaine when taken intravenously.

Who is the study for?
This trial is for individuals who understand the study procedures, have cocaine use disorder, and are willing to provide written informed consent. For more specific eligibility details, interested participants should contact the study site directly.Check my eligibility
What is being tested?
The study aims to investigate how intravenous (IV) cocaine interacts with a drug called GBR 12909. The focus is on understanding any potential effects when these substances are combined in individuals with cocaine use disorder.See study design
What are the potential side effects?
Specific side effects related to the interaction between IV cocaine and GBR 12909 will be studied; however, detailed information about possible side effects has not been provided here. Contacting the study site may yield further insights.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pharmacokinetic parameter comparison

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)Lead Sponsor
2,468 Previous Clinical Trials
2,619,325 Total Patients Enrolled
Louis Cantilena, M.D.Principal InvestigatorUniformed Services University of Health Science
6 Previous Clinical Trials
84 Total Patients Enrolled

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT00051896 — Phase 1
Cocaine Use Disorder Research Study Groups:
Cocaine Use Disorder Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT00051896 — Phase 1
Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT00051896 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there an ongoing recruitment process for this clinical trial?

"The information found on clinicaltrials.gov indicates that this specific research is no longer recruiting participants, as the study was last updated in January of 2017. Luckily, there are 18 other medical trials currently open for enrollment at present."

Answered by AI

What level of risk do individuals experience when undergoing this treatment?

"This experimental treatment has limited safety and efficacy data, thus our team assigned a score of 1 on the risk scale."

Answered by AI

Who is eligible to participate in this trial?

"In order to be considered for this cocaine-related clinical trial, volunteers should fall within the 18 - 45 age range. The study is searching for 24 willing participants."

Answered by AI

Is participation in this research limited to individuals 18 years or older?

"This clinical trial is recruiting patients aged between 18 and 45."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Assessment of the Potential Interactions Between Cocaine and GBR 12909 - 1
2002. "Assessment of the Potential Interactions Between Cocaine and GBR 12909 - 1". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00051896.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top